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Metastatic pancreatic cancer is rare, accounting for approximately 2% of all pancreatic malignancies, and most cases
arise from renal cell carcinoma. We report the case of a 63-year-old woman, who presented with a pancreatic tumor
detected during her annual health examination. She had undergone left nephrectomy 13 years previously for renal
cell carcinoma. Computed tomography (CT) revealed two tumors in the head and body of the pancreas, a
hypervascular tumor and a hypovascular tumor with an enhanced rim, respectively. She underwent pylorus-preserving
pancreaticoduodenectomy, and metastatic pancreatic tumors arising from the kidney with clustered clear cell
carcinoma immunohistochemically positive for CD10 were diagnosed. This report presents the different
enhancement features of different lesions on CT scans. Because the enhancement features of lesions have
been reported to vary according to the size of the metastatic tumor, a knowledge of the history of renal cell
carcinoma is crucial for diagnosis.
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Isolated metastasis to the pancreas is rare, ranging in inci-
dence from 2% to 5% in clinical studies [1-6]. Renal cell
carcinoma (RCC), melanoma, lung cancer, colorectal can-
cer and breast cancer are known to metastasize to the
pancreas [7-11]. Most patients with pancreatic metastases
are asymptomatic, whereas some exhibit jaundice or ab-
dominal pain [12]. RCC has an annual incidence of more
than 30,000 a year in the United States, and localized
disease is treated via nephrectomy. Of patients with
pancreatic metastases, 12% present with synchronous
extrapancreatic metastasis, and they have a poor prog-
nosis [13,14]. However, surgical treatment for isolated
metachronous pancreatic metastases from RCC has
been reported in recent years to improve prognosis
[6,13-17]. In this study, we report a case of pancreatic
metastases from RCC with different radiographic pat-
terns for each lesion and review the radiographic* Correspondence: ymailbiz@gmail.com
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reproduction in any medium, provided the orpatterns of pancreatic metastases using computed tom-
ography (CT) and fluorodeoxyglucose (FDG)-positron
emission tomography (PET).Case presentation
A 63-year-old woman had undergone left nephrectomy
for RCC at our hospital 13 years previously. After 5 con-
secutive years of follow-up, she underwent an annual
medical examination. Abdominal ultrasonography (US)
revealed an abnormal mass in the body of the pancreas.
CT revealed two lesions: a low-density mass (15 mm in
diameter) in the pancreatic body that displayed rim en-
hancement and a homogeneously enhanced mass (8 mm
in diameter) in the head (Figure 1). Magnetic resonance
imaging (MRI) did not show enhancement in either lesion.
FDG-PET did not show any abnormal metabolic activity
in the pancreas. To allow a pathological diagnosis, endo-
scopic ultrasonography (EUS)-guided fine-needle aspir-
ation biopsy was performed, but only necrotic tissue was
obtained from the specimen. Although the radiographic
features of the lesions were different, pancreatic metasta-
ses from RCC were strongly suspected because of thel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CT findings of the pancreatic metastases (arrows). a.
Homogenous hypervascular head lesion. b. body lesion with central
necrosis and enhanced rim.
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boratory findings: DUPAN-2, <25 U/ml (normal, <25 U/ml);
Span-1, 2.3 U/ml (normal, <30 U/ml); carcinoembryonic
antigen, 1.7 ng/ml (normal, <5.0 ng/ml); carbohydrate
antigen 19-9, 2.6 U/ml (normal, <37 U/ml) and gastrin,
480 pg/ml (normal, <200 pg/ml). The patient underwent
pylorus-preserving pancreaticoduodenectomy using the
Imanaga method [18]. For the R0 resection, an extended
pancreaticoduodenectomy was required rather than a
classical resection. Intraoperative US revealed a low echoic
mass with a bright halo and peripherally enriched blood
flow in the body and a low echoic mass with homoge-
neously enriched blood flow in the head. Gross patho-
logical examination revealed a 15 mm× 13 mm tumor
occupying the body of the pancreas and another 8-mm
tumor in the uncinate process of the pancreas. The head
lesion was soft, whereas the body lesion was firm in
consistency. The cut surface of the head lesion was yellow,
whereas that of the lesion in the pancreatic body was
grayish-white. Metastatic tumor cells homogeneously oc-
cupied the tumor in the head of the pancreas, and the firm
lesion in the body of the pancreas showed a necrotic
change in the center, which was surrounded by viable
tumor cells and a fibrous capsule, identified as a low-density
area on a CT scan (Figure 2). Immunohistochemically,the tumors were positive for CD10 and negative for
chromogranin A and synaptophysin (Figure 2). Microscopic
examination revealed large epithelial cells with clear cyto-
plasm and eosinophilic nuclei arranged in alveolar structures
with abundant vascularity (Figure 3a). In addition, histo-
logical examination revealed another 1-mm occult micro-
metastatic lesion in the head of the pancreas (Figure 3b).
The harvested lymph nodes and surgical margins were free
of malignancy. Taken together, the pathological findings in-
dicated that the lesions were metastases from RCC, and the
thick enhanced rim of the body lesion was believed to be
composed of viable RCC cells with high vascularity. The
postoperative course was uneventful, and to date the patient
has survived for 6 months without any evidence of recur-
rence or metastasis.
Discussion
RCC accounts for approximately 2% of all adult malig-
nances. Among kidney-limited diseases, RCC has a high
overall survival rate (up to 95%) [19]. However, 20% to
30% of patients have metastases at presentation, and the
5-year survival rate is less than 10% once metastases
spread [20]. In studies of resected specimens, RCC was
the most common primary tumor leading to isolated
pancreatic metastases [6,15]. RCC recurrence is classi-
fied as early or late recurrence. Late recurrence after
nephrectomy is not common: recurrence is seen in 10%
of patients after more than 10 years after surgery [21]. In
most studies, the development of pancreatic metastasis
was observed after a disease-free period after nephrec-
tomy exceeding 10 years (maximum, 32.7 years) [22].
The relation between the metastatic location of the pan-
creas and the primary RCC is controversial [23] and can
be either hematogeneous or via lymphatics [24]. Hema-
togeneous spread may occur along the draining collat-
eral vein of a hypervascular renal tumor, and the spread
through lymphatics may occur by retrograde lymph flow
secondary to tumor infiltration of the retroperitoneal
lymph nodes [25].
The symptoms of pancreatic metastasis are often non-
specific. Sellner et al. [13] reported in a review of 236
cases that 35% of patients were asymptomatic, whereas
other patients had abdominal pain (20%), gastrointes-
tinal tract bleeding (20%), obstructive jaundice (9%),
weight loss (9%), pancreatitis (3%) or diabetes mellitus
(3%). The diameter of the metastatic lesion was reported
to have some association with patient symptoms. Bassi
et al. [26] reported that the median tumor diameter in
asymptomatic patients was 25 mm, compared to 45 mm
in symptomatic patients. Conversely, Reddy et al. [27]
reported that 93% (42/45) of patients had symptoms
such as abdominal pain, jaundice or weight loss.
In general, the preoperative diagnosis of pancreatic
metastases begins with a suspicion based on the patient’s
Figure 2 Loupe images of resected specimen. The head lesion (a.c.) consist of tumor cells, whereas the body with necreotic change in the
center. a.c. Head lesion with hypervascular attenuation (a; H.E. stain, c; CD10). b.d. Body lesion with central hypodense (b; H.E. stain, d; CD10).
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PET and EUS support the diagnosis. Muranaka et al.
[29] reviewed the CT findings of pancreatic metastases
from 28 metastatic carcinomas and classified these into
3 types according to their configuration: (1) a single local-
ized metastasis (50% to 73%) [29-31]; (2) a diffuse enlarge-
ment with homogeneous attenuation of the pancreas (15%
to 44%) [29-31] and (3) multifocal metastases (5% to 10%)
[29-31]. Metastases from RCC are usually hypervascular
and consequently display homogeneous contrast medium
enhancement in the arterial phase of CT. Hyperenhance-
ment of pancreatic metastases from RCC plays an import-
ant role in both the detection of tumor locations and the
distinction of metastases from primary adenocarcinoma of
the pancreas [32]. When hypervascular pancreatic tumors
are identified on enhanced CT scans, differentiation from
primary pancreatic endocrine tumors, intrapancreatic
accessory spleens and vascular lesions is difficult.
Palmowski et al. [4] observed two types of enhancement
on CT scans of pancreatic metastases, namely lesions with
either a homogeneous enhancement or a highlighted rim
and nonenhancing internal components, depending on
the size. In lesions greater than 15 mm in size, rim en-
hancement with hypodense central areas of necrosis hasbeen observed on CT scans [32]. This hypodense aspect is
associated with colonic metastases, hyperdense attenu-
ation with RCC, or breast cancer [33,34]. We reviewed the
radiological features of pancreatic metastases from RCC
shown by dynamic CT scans (Table 1). Of 66 patients, 45
(68%) had homogeneous hypervascular enhancement fea-
tures, whereas 21 (32%) had central hypovascularity with
rim enhancement. Of these, 31 patients had a metastatic
configuration, 5 patients had multifocal metastases to the
pancreas and 26 patients had solitary tumors. No patients
with pancreatic metastasis from RCC developed diffuse
enlargement of the pancreas. In the present review, the
size of pancreatic metastases from RCC has no particular
relation with the presence of central hypodense areas be-
cause even tumors > 5 cm in size displayed hypervascular
attenuation. The present case was classified as one with
multifocal metastases in terms of the metastatic location.
To our knowledge, this is the first case of concomitant
multifocal metastases featuring two different enhance-
ment characteristics, hypodense areas and homogenous
hypervascularity.
FDG-PET has not been established for the diagnosis of
metastatic RCC. Ramdave et al. [45] reported that FDG-
PET was useful for identifying distant metastases from
Figure 3 Microscopic findings revealed clear cell carcinoma in
all metastatic lesions including head, body and occult tumor.
a. Magnification of Head tumor with haematoxylin and eosin (H.E.)
stain x100. b. metastatic tumor found occasionally in the head of
the pancreas (1 mm) x40.
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[46] calculated the sensitivity and specificity of FDG-
PET for identifying distant metastases from RCC. They
revealed that the sensitivity of the procedure was linked
to the size of the metastases (83% for lesions larger than
15 mm; 93% for those larger than 20 mm). In the
present patient with 15- and 8-mm lesions, FDG did not
indicate any abnormal metabolic activity in either lesion.
Surgical resection of the pancreas is associated with
substantial morbidity after surgery, and the survival
benefit of surgery for metastatic lesions of the pancreas
remains questionable since randomized control trials
have not been conducted. However, surgical resection of
metastatic deposits of RCC remains the most effective
treatment because chemotherapy, immunotherapy and
radiotherapy have generally proved to be ineffective for
metastatic RCC [14,22,25,47]. We reviewed studies
published from 1998 to 2013 that focused on surgicalresection of the pancreas for metastases from RCC. The
survival rates and features are listed in Table 2. The me-
dian 5-year overall survival rate after metastasectomy
was reported to be 75% to 88%, compared to 0% to 50%
without metastasectomy [13,14,17]. In a review, Masetti
et al. [48] analyzed data for 159 patients who underwent
metastasectomy of the pancreas for RCC: the median
survival and 5-year survival rate were 5.8 years and
63.5%, respectively. Tanis et al. [49] reviewed 170 arti-
cles, and data for a total of 411 patients who underwent
resection of pancreatic metastases were analyzed. They
reported a pancreatic recurrence rate of 4.0% after a me-
dian of 42 months and an extrapancreatic recurrence
rate of 17.1%. The 5-year survival rate was 72.6%. The
surgical mortality rate after pancreaticoduodenectomy
for pancreatic metastases was reported to be 2.6% [23].
Sellner et al. [13] compared the 5-year overall survival
rate of patients with a solitary metastasis with those with
multiple metastases (solitary metastasis, 64%; multiple
metastases, 78%). Combining the findings outlined in
several reports [50-52], radical surgery for multifocal
metastases from RCC in the pancreas appears to be as
justified as that for a solitary metastasis. Radical surgery
with the R0 resection is the only curative option for pa-
tients with pancreatic metastases. Therefore, surgical re-
section for pancreatic metastases should be considered
under individualized conditions including the manage-
ment of comorbidities.Conclusions
Multifocality of pancreatic metastasis has been re-
ported to be in the range 20% to 45% [13,14]. In
one report, a preoperative multifocality detection of
17.4% increased up to 34.8% on pathological examin-
ation of resected specimens [14]. Here, we report a
rare case of pancreatic metastases with micrometas-
tasis, which was not detected preoperatively, in the
resected pancreas specimen on pathological examin-
ation. Moreover, pancreatic metastases from RCC
can show both hypervascular attenuation and are
central hypodense on CT scans although they are
generally hypervascular tumors. Careful examination
with multiple modalities for the diagnosis of the meta-
static configuration and follow-up are recommended
after surgery.Consent
Written informed consent was obtained from the
patient for publication of this case report and any
accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this
journal.
Table 2 Literature review of surgical treatment for pancreatic metastases from RCC
Reference Year Number of
patientsa








Butturini et al. [53] 1998 5 63 2:3 NA 24.5 120 (24–276) 19
Kassabian et al. [54] 2000 5 56 1:4 67% NA 144 (48–180) 48
Ghavamian et al. [55] 2000 11 68 3:8 81% 120 108 (18–295) 50
Sohn et al. [17] 2001 10 63 4:6 80% 7 102 (0–336) 8
Faure et al. [36] 2001 8 57 2:6 88% NA 83 (12–120) 38
Yachida et al. [37] 2002 5 60 2:3 100% 12 144 (36–288) 18
Law et al. [56] 2003 14 64 9:5 75% NA 78 (0–300) 130
Wente et al. [47] 2005 15 63 10:5 NA NA 85 (0–258) 10
Crippa et al. [6] 2006 5 65 3:2 80% NA 36 (22–192) 41
Eidt et al. [15] 2007 7 64 2:5 88% NA 160 (108–240) 36
Varker et al. [57] 2007 5 NA NA 60% NA 175 NA
Schauer et al. [58] 2008 10 62 5:5 60% 33 128 (5–277) 56
Zerbi et al. [14] 2008 23 64 15:8 88% 27 96 (12–276) 31
Reddy et al. [27] 2008 21 60 11:10 45% 58 110 over 120
Tanis et al. [49] 2009 10 63.5 2:8 NA NA 107 (5–228) NA
Masetti et al. [48] 2010 6 62 6:0 NA NA 57.6 (20–288) 3
Konstantinidis et al. [59] 2010 20 68.5 7:13 61% 104 104 NA
Yazbek et al. [44] 2012 11 73 1:10 90% 84 136 (12–240) NA
Gardini et al. [60] 2012 8 68 4:4 NA NA NA 38.6
NA: not available.
aStudies that included less than four patients were excluded.
Table 1 Radiologic features of pancreatic metastases from renal cell carcinoma shown by computed tomography








Marunaka et al. [29] 1989 1 0 1 1 0
Boudghene et al. [33] 1994 3 2 5 NA NA
Scatarige et al. [35] 2001 1 1 2 2 0
Faure et al. [36] 2001 5 3 8 NA NA
Yachida et al. [37] 2002 1 0 1 1 0
Zacharoulis et al. [38] 2003 3 0 3 2 1
David et al. [25] 2006 0 1 1 1 0
Palmowski et al. [4] 2008 12 10 22 NA NA
Mecho et al. [39] 2009 4 2 6 6 0
You et al. [40] 2011 2 0 2 0 2
Katsourakis et al. [41] 2012 1 0 1 1 0
Atiq et al. [42] 2012 2 2 4 3 1
Comunoglu et al. [43] 2012 1 0 1 0 1
Yazbek et al. [44] 2012 9 0 9 9 0
Totals 45 21 66 26 5
NA, not available.
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